


- 29 -


CLAIMS

1. A compound of the formula:



wherein:

X is selected from the group consisting of trihalomethyl, C₁-C₆ alkyl,
and a group of formula II:



wherein:

R₃ and R₄ are independently selected from the group
consisting of hydrogen; halogen; hydroxyl; nitro; C₁-C₆ alkyl;
C₁-C₆ alkoxy; carboxy; C₁-C₆ trihaloalkyl; and cyano;

Z is selected from the group consisting of substituted and
unsubstituted aryl; or a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1 wherein Z is selected from
the group consisting of substituted and unsubstituted heteroaryl; or a
pharmaceutically acceptable salt thereof.

3. A compound according to claim 2 wherein Z is selected from
the group consisting of substituted and unsubstituted indolyl, furyl, thienyl,
pyridyl, benzofuryl, benzothienyl, imidazolyl, pyrazolyl, thiazolyl,
benzothazolyl, quinolinyl, and 4-(2-benzyloxazolyl); or a pharmaceutically

- 30 -

acceptable salt thereof.

4. A compound according to claim ¹~~4~~ wherein Z is 3-indolyl; or a pharmaceutically acceptable salt thereof.

5. A compound according to claim 1 wherein X is trifluoromethyl.


5 6. A compound according to claim 1 wherein X is a group according to formula II wherein R₃ and R₄ are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C₁-C₆ alkyl; C₁-C₆ alkoxy; carboxy; C₁-C₆ trihaloalkyl; and cyano; or a pharmaceutically acceptable salt thereof.

10 7. A compound according to claim 6 wherein R₃ and R₄ are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C₁-C₆ alkyl; C₁-C₆ alkoxy; and carboxy; or a pharmaceutically acceptable salt thereof.

8. A compound according to claim 7 wherein Z is selected from the group consisting of unsubstituted phenyl; and mono-, di- and tri-substituted phenyl.

8 ~~10~~ 9. A compound according to claim ²~~8~~ wherein Z is phenyl substituted with one or more of halogen, hydroxyl, nitro, C₁-C₆ alkyl, C₁-C₆ alkoxy, or carboxy; or a pharmaceutically acceptable salt thereof.

20 9 ~~10~~ 10. A compound according to claim ¹⁰~~9~~ wherein Z is the group



wherein R₁ and R₂ are independently selected from the group consisting of

- 31 -

hydrogen, fluorine, bromine, chlorine, C₁-C₃ alkyl, C₁-C₃ alkoxy, hydroxyl and nitro; or a pharmaceutically acceptable salt thereof.

5

11. A compound according to claim 7 wherein Z is substituted or unsubstituted indolyl, furyl, thienyl, pyridyl or benzofuryl; or a pharmaceutically acceptable salt thereof.

12. A compound according to claim 11 wherein 11 is 3-indolyl; or a pharmaceutically acceptable salt thereof.

10


13. The compound according to claim 1 which is 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-phenyl-2-pyrazoline; or a pharmaceutically acceptable salt thereof.

14. The compound according to claim 1 which is 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-(3-indolyl)-2-pyrazoline; or a pharmaceutically acceptable salt thereof.

15

17
15

A compound of the formula V:




p5

wherein:

p1

X is selected from the group consisting of trihalomethyl, C₁-C₆ alkyl, and a group of formula II:

- 32 -



p1 wherein:

p2 R₃ and R₄ are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C₁-C₆ alkyl; C₁-C₆ alkoxy; carboxy; C₁-C₆ trihaloalkyl; and cyano;

5

p1
L

Z is substituted or unsubstituted heteroaryl; and

R₅ is selected from the group consisting of




p5 wherein R₆ is C₁-C₆ alkyl and M is Na, K or Li; or a pharmaceutically acceptable salt thereof.

10


~~10~~
16.

A compound of the formula V:



p5 wherein:

p1 X is a group of formula II:



- 33 -

p1

wherein:

p2

R_3 and R_4 are independently selected from the group consisting of hydrogen; halogen; hydroxyl; nitro; C_1 - C_6 alkyl; C_1 - C_6 alkoxy; carboxy; C_1 - C_6 trihaloalkyl; and cyano;

5 p1

Z is selected from the group consisting of substituted and unsubstituted aryl; and

p1

R_5 is selected from the group consisting of



50350

p5

wherein R_6 is C_1 - C_6 alkyl and M is Na, K or Li; or a pharmaceutically acceptable salt thereof.


17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to any of claims 1, 15 or 16, or a pharmaceutically acceptable salt thereof.

15 18. A method for treating a cyclooxygenase-mediated disorder comprising administering to a patient in need of such treatment an effective amount of a compound according to any of claims 1, 15 or 16, or a pharmaceutically acceptable salt thereof.

20 19. A method for treating inflammation or an inflammation-mediated disorder comprising administering to a subject in need of such treatment an effective amount of a compound according to any of claims 1, 15 or 16, or a pharmaceutically acceptable salt thereof.

20. A method for treating a neoplasia comprising administering to a subject in need of such treatment an effective amount of a compound according to any of claims 1, 15 or 16, or a pharmaceutically acceptable

- 35 -




wherein X and Z are so defined;
 with 4-sulfamyl phenyl hydrazine or salt thereof; and
 (b) isolating a compound according to formula I from the reaction products.

5

²⁵
~~23.~~ A method according to claim ²⁴~~22~~ wherein Z is substituted or unsubstituted heteroaryl.

²⁶
~~24.~~ A method according to claim ²⁴~~22~~ wherein X is a radical of formula II.

²⁵
~~25.~~ A method according to claim 22 wherein the group X in the reactant compound of formula II is selected from the group consisting of trifluoromethyl, C₁-C₆ alkyl, and a radical of formula II:



wherein:

wherein R₃ and R₄ are independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, C₁-C₆ alkyl, C₁-C₆ alkoxy; and carboxy.

15


26. An isolated optical isomer of a compound according to any of claims 1, 15 or 16, or a pharmaceutically acceptable salt thereof.

- 34 -

salt thereof.


21. A method for treating an angiogenesis-mediated disorder administering to a subject in need of such treatment an effective amount of a compound according to any of claims 1, 15 or 16, or a pharmaceutically acceptable salt thereof.

22. A method for producing a compound of formula I



wherein:

the group X is selected from the group consisting of trihalomethyl, C₁-C₆ alkyl, and a radical of formula II:



wherein:

wherein R₃ and R₄ are independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, C₁-C₆ alkyl, C₁-C₆ alkoxy; carboxy; C₁-C₆ trihaloalkyl; and cyano; and

Z is selected from the group consisting of substituted and unsubstituted aryl;

the method comprising:

(a) reacting a compound of the formula IV

009595760-061600